Anakinra
Anakinra is a recombinant human interleukin-1 receptor antagonist (IL-1Ra). It competitively inhibits binding of IL-1α and IL-1β to the IL-1 receptor type 1. Given daily as subcutaneous injection, it has modest but significant anti-inflammatory efficacy in Rheumatoid arthritis and has been proven of particular benefit in autoinflammatory syndromes, where IL-1 seems to play a pivotal role.
Anakinra has been reported to be useful in refractory seizures in the chronic phase of FIRES[1].
References
1.
a
Therapeutic effect of Anakinra in the relapsing chronic phase of febrile infection-related epilepsy syndrome. Epilepsia Open. 2019 Mar 27;4(2):344-350. doi: 10.1002/epi4.12317. eCollection 2019 Jun.
[PMID: 31168503] [PMCID: 6546072] [DOI: 10.1002/epi4.12317] .
[PMID: 31168503] [PMCID: 6546072] [DOI: 10.1002/epi4.12317] .
Discussion